Stacy Merrifield, DO
Family Medicine · Puyallup, WANPI 1497967103
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $544 and has fallen 95.5% since, to $25 in 2025.
Across 42 payments — averaging $21.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Si-bone, Inc.$180
- Johnson & Johnson$91
- Amgen$71
- Novo Nordisk$68
- Novartis$65
- Pfizer$57
- plus $367 from 14 others
What the payments were for
- Food & beverage$897100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Si-bone, Inc. | 2 | $180 |
| Johnson & Johnson | 4 | $91 |
| Amgen | 4 | $71 |
| Novo Nordisk | 4 | $68 |
| Novartis | 3 | $65 |
| Pfizer | 3 | $57 |
| Daiichi Sankyo Inc. | 2 | $42 |
| Boehringer Ingelheim | 2 | $38 |
| AbbVie | 3 | $38 |
| Genentech USA, Inc. | 2 | $35 |
| Lilly USA, LLC | 2 | $35 |
| GSK | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Nevro Corp. | 1 | $20 |
| Shire North American Group Inc | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| Merck | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
How this compares
$897 in reported general payments places this provider in the 80th percentile of 2,275 family medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 15 | $5,149 |
| Gabapentin | 45 | $2,015 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 19 | $1,236 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $879 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $835 |
| Bupropion XlBupropion Hcl | 24 | $755 |
| Omeprazole | 46 | $726 |
| Levothyroxine Sodium | 98 | $685 |
| Oxycodone Hcl | 39 | $672 |
| Mirtazapine | 20 | $567 |
| Atorvastatin Calcium | 48 | $514 |
| Pravastatin Sodium | 20 | $509 |
| Paroxetine Hcl | 13 | $441 |
| Lamotrigine | 11 | $408 |
| Lisinopril | 57 | $391 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Puyallup
- William KriegsmanPuyallup$41K
- Daria SciarronePuyallup$26K
- Katherine BrewerPuyallup$17K
- Eugenia GurayPuyallup$10K
- John DanielPuyallup$9K
- Kevin HatfieldSeattle$527K
- Marta KazymyraBlaine$222K
- Donella YoungDavenport$175K
- Robert McIntyreSeattle$107K
- James MorenBellingham$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.